Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CORT

Corcept Therapeutics Inc

Apr 10 • 04:00PM ET

41.91

-0.34 -0.80 %

Healthcare • Biotechnology • USA • NASD

Peers: NBIX SRPT TGTX MDGL ARDX ANAB VKTX AKBA LGND PSTV

| Held by: IJR VTI FBT VB VBK VXF SPSM IJT IWP SLYG

Scroll to Statements

Index	-	P/E	51.23	EPS (ttm)	0.82	Insider Own	11.89%	Shs Outstand	105.97M	Perf Week	-1.37%
Market Cap	4.46B	Forward P/E	32.21	EPS next Y	1.30	Insider Trans	-1.43%	Shs Float	93.73M	Perf Month	24.21%
Enterprise Value	4.09B	PEG	0.62	EPS next Q	-0.11	Inst Own	71.78%	Short Float	13.28%	Perf Quarter	14.73%
Income	98.16M	P/S	5.86	EPS this Y	-54.16%	Inst Trans	-0.47%	Short Ratio	6.29	Perf Half Y	-52.61%
Sales	761.41M	P/B	6.86	EPS next Y	246.10%	ROA	11.70%	Short Interest	12.45M	Perf YTD	20.43%
Book/sh	6.11	P/C	11.98	EPS next 5Y	52.26%	ROE	14.79%	52W High	91.00 -53.95%	Perf Year	-38.12%
Cash/sh	3.50	P/FCF	31.44	EPS past 3/5Y	-2.15% -0.84%	ROIC	15.04%	52W Low	28.66 46.23%	Perf 3Y	85.20%
Dividend Est.	-	EV/EBITDA	87.64	Sales past 3/5Y	23.74% 16.56%	Gross Margin	98.30%	Volatility	4.22% 6.47%	Perf 5Y	84.79%
Dividend TTM	-	EV/Sales	5.37	EPS Y/Y TTM	-30.18%	Oper. Margin	5.88%	ATR (14)	2.34	Perf 10Y	753.56%
Dividend Ex-Date	-	Quick Ratio	2.82	Sales Y/Y TTM	12.79%	Profit Margin	12.89%	RSI (14)	61.55	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	2.89	EPS Q/Q	-22.26%	SMA20	10.96%	Beta	0.28	Target Price	67.40
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	11.12%	SMA50	11.55%	Rel Volume	0.43	Prev Close	42.25
Employees	730	LT Debt/Eq	0.01	Earnings	Feb 24 AMC	SMA200	-33.09%	Avg Volume	1.98M	Price	41.91
IPO	Apr 14, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	-39.30% -21.32%	Trades		Volume	842,811	Change	-0.80%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-26	Upgrade	Wolfe Research	Underperform → Peer Perform
Dec-31-25	Downgrade	Wolfe Research	Peer Perform → Underperform	$30
Dec-16-25	Initiated	UBS	Neutral
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Nov-06-23	Upgrade	Truist	Hold → Buy	$29 → $38
Apr-11-23	Initiated	SVB Securities	Market Perform	$25
Apr-04-23	Initiated	Piper Sandler	Overweight	$27
Feb-15-23	Downgrade	Jefferies	Buy → Hold	$35 → $22
Aug-01-22	Downgrade	Truist	Buy → Hold	$30
Jul-27-22	Upgrade	Jefferies	Hold → Buy	$21 → $35
Jun-27-22	Resumed	Canaccord Genuity	Buy	$30 → $34
Feb-02-22	Initiated	Canaccord Genuity	Buy	$30
Jan-28-22	Initiated	Truist	Buy	$30
Aug-05-20	Downgrade	Jefferies	Buy → Hold	$16
Sep-24-19	Initiated	Jefferies	Buy	$20
Sep-06-19	Initiated	H.C. Wainwright	Buy	$18
Feb-04-19	Downgrade	B. Riley FBR	Buy → Neutral	$22 → $12
Aug-10-18	Reiterated	Stifel	Hold	$20 → $11
May-31-18	Downgrade	Stifel	Buy → Hold	$20
Mar-09-18	Initiated	B. Riley FBR, Inc.	Buy	$30

Show Previous Ratings

Today 04:45PM	Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Mar-28-26 02:45PM	Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session (Business Wire)
Mar-26-26 02:10PM	Corcepts first-in-class ovarian cancer drug gains FDA approval (Pharmaceutical Technology)
Mar-25-26 12:43PM	FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer (Business Wire) +19.66%
Mar-24-26 08:49AM	Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately (PR Newswire)
05:35PM	Loading…
Mar-18-26 05:35PM	Robbins LLP Urges CORT Stockholders to Contact the Firm for Information About the Class Against Corcept Therapeutics Incorporated (PR Newswire)
09:00AM	Shareholders of Corcept Therapeutics Incorporated Should Contact Levi & Korsinsky Before April 21, 2026 to Discuss Your Rights - CORT (PR Newswire)
Mar-16-26 03:27AM	Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT (PR Newswire)
Mar-12-26 04:32AM	Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT (PR Newswire)
Mar-09-26 02:37AM	Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT (PR Newswire)
Mar-05-26 08:29AM	Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead? (Zacks)
Feb-27-26 02:54AM	Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT (PR Newswire)
Feb-25-26 08:03PM	Corcept Therapeutics Incorporated Q4 2025 Earnings Call Summary (Moby)
09:12AM	Corcept's Q4 Earnings and Revenues Fall Short of Estimates (Zacks)
07:15AM	Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights CORT (Business Wire)
12:01AM	Loading…
12:01AM	Corcept Therapeutics Inc (CORT) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
Feb-24-26 11:11PM	Corcept Therapeutics Q4 Earnings Call Highlights (MarketBeat)
09:55PM	Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates (Zacks)
05:13PM	Corcept: Q4 Earnings Snapshot (Associated Press Finance)
04:49PM	Corcept (NASDAQ:CORT) Misses Q4 CY2025 Sales Expectations (StockStory)
04:05PM	Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update (Business Wire)
08:06AM	Is Corcept Therapeutics Incorporated (CORT) at an inflection point? (Insider Monkey)
Feb-22-26 10:12PM	Corcept (CORT) Q4 Earnings: What To Expect (StockStory)
Feb-19-26 04:00PM	Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals (Business Wire) -14.01%
01:03PM	Stocks Fall, Oil Hits 7-Month High As Trump Weighs Iran Strike: What's Moving Markets Thursday? (Benzinga)
11:48AM	Corcept Therapeutics Stock Plunges As Court Clears Teva Generic (Benzinga)
Feb-17-26 04:05PM	Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call (Business Wire)
Feb-16-26 12:24PM	FDA-Issued CRL for Relacorilant NDA Leads to Bullish Views Around Corcept Therapeutics (CORT) (Insider Monkey)
Feb-04-26 03:31PM	Lost Money on Corcept Therapeutics Incorporated (CORT)? Possible Fraud - Contact Levi & Korsinsky Today (Newsfile)
Jan-30-26 08:32PM	Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing (Business Wire) -10.63%
06:44PM	Loading…
Jan-25-26 06:44PM	Corcept Therapeutics (CORT) Climbs 26.6% on Stellar Clinical Trial Result (Insider Monkey)
Jan-23-26 01:55PM	Silver Breaks $101, Intel Stock Plunges 17%: What's Moving Markets Friday? (Benzinga) +6.49%
11:13AM	CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study (Zacks)
08:11AM	Corcept Therapeutics (CORT) Climbs 13.7% on Strong Clinical Trial Results (Insider Monkey)
05:27AM	Novo climbs higher on strong Wegovy pill launch; Terns tweaks leukemia drug deal (BioPharma Dive)
Jan-22-26 04:05PM	Why Former Highflier Corcept Therapeutics Just Surged Again (Investor's Business Daily) +13.74%
03:06PM	Russell 2000 Extends Records, Meta Jumps 5%: What's Moving Markets Thursday? (Benzinga)
01:07PM	Corcepts stock up as relacorilant meets OS goal in Phase III ovarian cancer trial (Clinical Trials Arena)
11:12AM	Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps (Benzinga)
08:00AM	Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Jan-15-26 08:15AM	Is Corcept Therapeutics Incorporated (CORT) The Most Promising Growth Stock According to Analysts? (Insider Monkey)
06:47AM	One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit (24/7 Wall St.)
Jan-14-26 11:56AM	Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman (PR Newswire)
Jan-09-26 03:16AM	Price Targets Lowered on Corcept Therapeutics (CORT) After FDA Letter (Insider Monkey)
Jan-06-26 12:01PM	Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman (PR Newswire)
Jan-05-26 11:31PM	1 Healthcare Stock to Target This Week and 2 We Turn Down (StockStory) -8.51%
12:16PM	Why Corcept (CORT) Stock Is Trading Lower Today (StockStory)
09:54AM	Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Jan-02-26 11:17AM	The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away (Barchart) +9.77%
10:22AM	Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism (Zacks)
08:50AM	Implied Volatility Surging for Corcept Stock Options (Zacks)
07:30AM	Company News for Jan 2, 2026 (Zacks)
Jan-01-26 08:10AM	FDA says it needs additional evidence of effectiveness for Corcept relacorilant (TipRanks)
Dec-31-25 06:41PM	Why Corcept Therapeutics Plummeted by 50% Today (Motley Fool) -50.42% +9.77%
05:00PM	Why Corcept (CORT) Shares Are Falling Today (StockStory)
04:34PM	Stocks Settle Lower on Tech Weakness and Higher Bond Yields (Barchart)
12:31PM	Corcept Therapeutics Shares Plunge 50% After FDA Rejects Blood Pressure Drug (Barrons.com)
10:00AM	Corcept Sinks After FDA Rejects Drug to Treat Hypertension (Bloomberg)
09:57AM	Stocks Slide on Weakness in Megacap Tech Stocks (Barchart)
08:00AM	Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism (Business Wire)
Dec-30-25 06:32AM	Stock Market Today: Stocks Struggling to Finish 2025 on High Note (TheStreet) -12.06%
Dec-23-25 03:51PM	Why Corcept (CORT) Stock Is Trading Lower Today (StockStory)
Dec-21-25 08:56AM	Corcept Therapeutics (CORT): Analyst Says Shares Pricing in Growth, New Launch (Insider Monkey)
Dec-16-25 11:03PM	Corcept (CORT): Buy, Sell, or Hold Post Q3 Earnings? (StockStory) -7.08%
02:05PM	Why Corcept (CORT) Stock Is Down Today (StockStory)
Dec-11-25 07:44AM	Wall Street Firms Tout Corcept Therapeutics Incorporated (CORT) Prospects on Korlym Medication Prospects (Insider Monkey)
Dec-10-25 11:30AM	Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-07-25 10:33PM	Analysts See 70% Upside Potential in Corcept Therapeutics (CORT) Stock (Insider Monkey)
Dec-04-25 11:30AM	Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-01-25 11:04AM	Will Korlym Continue to Drive Corcept's Top Line in 2026? (Zacks)
Nov-26-25 02:59PM	Corcept Therapeutics Incorporated (CORT) Modifies Revenue Guidance while Banking on Cushing Syndrome Treatment for Growth (Insider Monkey)
Nov-12-25 10:34PM	Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Corcept (NASDAQ:CORT) (StockStory)
Nov-11-25 12:36AM	The 5 Most Interesting Analyst Questions From Corcept's Q3 Earnings Call (StockStory)
Nov-05-25 10:01AM	Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down (Zacks) +7.81%
08:31AM	CORT Q3 Deep Dive: Pharmacy Transition and Pipeline Expansion Drive Mixed Outlook (StockStory)
12:10AM	Corcept Therapeutics Inc (CORT) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Net ... (GuruFocus.com)
Nov-04-25 06:25PM	Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates (Zacks)
06:00PM	Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q3 Earnings (StockStory)
05:20PM	Corcept: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update (Business Wire)
09:36AM	What Does Wall Street Think About Corcept Therapeutics (CORT)? (Insider Monkey)
Nov-02-25 10:04PM	Corcept Earnings: What To Look For From CORT (StockStory)
Oct-29-25 10:00AM	NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 04:05PM	Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call (Business Wire)
Oct-22-25 10:00AM	Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-19-25 05:15AM	Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment (Business Wire)
Oct-17-25 09:54PM	H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) (Insider Monkey)
Oct-15-25 02:02PM	Corcept (CORT) Shares Skyrocket, What You Need To Know (StockStory) +6.50%
11:35AM	CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer (Zacks)
Oct-14-25 08:00AM	Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Oct-10-25 11:51AM	Why Corcept (CORT) Shares Are Falling Today (StockStory) -16.30%
Oct-03-25 08:21AM	Here's What Makes Corcept Therapeutics (CORT) an Attractive Investment? (Insider Monkey)
Oct-01-25 04:01PM	Why Corcept (CORT) Stock Is Trading Up Today (StockStory)
10:40AM	Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym? (Zacks)
Sep-29-25 07:20PM	Corcept Therapeutics Beats Q2 Estimates, Cuts Guidance and Advances NDA for New Cancer Drug (Insider Monkey)
Sep-24-25 04:06AM	FDA Accepts New Drug Application for Corcept Therapeutics's (CORT) Relacorilant (Insider Monkey)
Sep-23-25 03:25PM	Why Are Corcept (CORT) Shares Soaring Today (StockStory)
Sep-22-25 02:30PM	Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025 (Business Wire)
Sep-16-25 12:02AM	Corcept (CORT): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Sep-15-25 11:36PM	Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment (StockStory)

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guyer William	Chief Development Officer	Apr 07 '26	Option Exercise	21.65	20,000	433,000	22,231	Apr 08 07:34 PM
Guyer William	Chief Development Officer	Apr 07 '26	Sale	40.97	20,000	819,400	2,231	Apr 08 07:34 PM
Guyer William	Officer	Apr 07 '26	Proposed Sale	40.85	20,000	817,000		Apr 07 12:08 PM
BELANOFF JOSEPH K	Chief Executive Officer	Mar 25 '26	Sale	50.07	26,198	1,311,826	2,918,326	Mar 27 04:27 PM
BELANOFF JOSEPH K	Officer	Mar 25 '26	Proposed Sale	33.82	40,000	1,352,800		Mar 25 03:49 PM
Guyer William	Chief Development Officer	Mar 20 '26	Option Exercise	21.65	11,767	254,756	13,998	Mar 24 04:54 PM
Guyer William	Chief Development Officer	Mar 20 '26	Sale	36.01	11,767	423,730	2,231	Mar 24 04:54 PM
BAKER G LEONARD JR	Director	Mar 17 '26	Buy	33.14	100,000	3,313,809	1,146,631	Mar 19 05:07 PM
MAHONEY DAVID L	Director	Mar 13 '26	Option Exercise	5.86	30,000	175,800	30,000	Mar 17 07:52 PM
Guyer William	Chief Development Officer	Mar 04 '26	Option Exercise	21.65	8,233	178,244	10,464	Mar 06 04:30 PM
Guyer William	Chief Development Officer	Mar 04 '26	Sale	35.99	8,233	296,346	2,231	Mar 06 04:30 PM
Guyer William	Officer	Mar 04 '26	Proposed Sale	35.28	20,000	705,600		Mar 04 04:02 PM
WILSON JAMES N	Director	Feb 24 '26	Option Exercise	3.88	100,000	388,000	100,000	Feb 26 04:45 PM
Hunt Hazel	Chief Scientific Officer	Feb 09 '26	Option Exercise	3.88	150,000	582,000	333,405	Feb 11 05:26 PM
Guyer William	Chief Development Officer	Feb 03 '26	Option Exercise	21.65	20,000	433,000	21,235	Feb 05 05:42 PM
Guyer William	Chief Development Officer	Feb 03 '26	Sale	40.87	20,000	817,334	1,235	Feb 05 05:42 PM
Guyer William	Officer	Feb 03 '26	Proposed Sale	40.71	20,000	814,200		Feb 03 11:26 AM
BAKER G LEONARD JR	Director	Jan 27 '26	Option Exercise	11.49	140,000	1,608,700	1,095,262	Jan 29 04:10 PM
Guyer William	Chief Development Officer	Jan 06 '26	Option Exercise	21.65	20,000	433,000	21,235	Jan 08 08:35 PM
Guyer William	Chief Development Officer	Jan 06 '26	Sale	35.18	20,000	703,656	1,235	Jan 08 08:35 PM
Guyer William	Officer	Jan 06 '26	Proposed Sale	34.95	20,000	699,000		Jan 06 12:04 PM
Robb Gary Charles	Chief Business Officer	Dec 24 '25	Option Exercise	3.88	145,000	562,600	158,910	Dec 29 05:58 PM
BELANOFF JOSEPH K	Chief Executive Officer	Dec 24 '25	Option Exercise	3.88	550,000	2,134,000	550,000	Dec 29 05:24 PM
Guyer William	Chief Development Officer	Dec 02 '25	Option Exercise	21.65	20,000	433,000	21,235	Dec 03 09:19 PM
Guyer William	Chief Development Officer	Dec 02 '25	Sale	80.08	20,000	1,601,526	1,235	Dec 03 09:19 PM
Maduck Sean	See Remarks	Dec 01 '25	Option Exercise	8.27	20,000	165,400	27,904	Dec 03 08:53 PM
Maduck Sean	See Remarks	Dec 01 '25	Sale	79.52	20,000	1,590,490	7,904	Dec 03 08:53 PM
Lyon Joseph Douglas	See Remarks	Dec 01 '25	Option Exercise	13.56	5,000	67,800	15,277	Dec 03 08:36 PM
Lyon Joseph Douglas	See Remarks	Dec 01 '25	Sale	79.53	5,000	397,632	10,277	Dec 03 08:36 PM
BELANOFF JOSEPH K	Chief Executive Officer	Dec 01 '25	Sale	79.77	40,000	3,190,796	2,701,370	Dec 03 08:14 PM
Guyer William	Officer	Dec 02 '25	Proposed Sale	79.78	20,000	1,595,600		Dec 02 10:34 AM
BELANOFF JOSEPH K	Officer	Dec 01 '25	Proposed Sale	79.40	40,000	3,176,000		Dec 01 02:36 PM
Maduck Sean	Officer	Dec 01 '25	Proposed Sale	79.40	20,000	1,588,000		Dec 01 02:00 PM
Lyon Joseph Douglas	Officer	Dec 01 '25	Proposed Sale	79.40	5,000	397,000		Dec 01 01:50 PM
Guyer William	Chief Development Officer	Nov 25 '25	Sale	80.90	4,500	364,070	787	Nov 26 05:22 PM
Guyer William	Officer	Nov 25 '25	Proposed Sale	80.90	4,500	364,070		Nov 25 04:46 PM
Guyer William	Chief Development Officer	Nov 05 '25	Option Exercise	21.65	20,000	433,000	25,287	Nov 07 05:10 PM
Guyer William	Chief Development Officer	Nov 05 '25	Sale	75.36	20,000	1,507,122	5,287	Nov 07 05:10 PM
Lyon Joseph Douglas	See Remarks	Nov 03 '25	Option Exercise	13.56	5,000	67,800	15,277	Nov 05 07:59 PM
Lyon Joseph Douglas	See Remarks	Nov 03 '25	Sale	73.65	5,000	368,244	10,277	Nov 05 07:59 PM
BELANOFF JOSEPH K	Chief Executive Officer	Nov 05 '25	Sale	74.77	28,782	2,152,105	2,741,370	Nov 05 07:57 PM
BELANOFF JOSEPH K	Chief Executive Officer	Nov 03 '25	Sale	74.08	11,218	831,014	2,770,152	Nov 05 07:57 PM
Maduck Sean	See Remarks	Nov 03 '25	Option Exercise	8.27	20,000	165,400	27,904	Nov 05 07:56 PM
Maduck Sean	See Remarks	Nov 03 '25	Sale	73.99	20,000	1,479,816	7,904	Nov 05 07:56 PM
Guyer William	Officer	Nov 05 '25	Proposed Sale	71.10	20,000	1,422,000		Nov 05 10:12 AM
BELANOFF JOSEPH K	Officer	Nov 03 '25	Proposed Sale	73.47	40,000	2,938,800		Nov 03 04:06 PM
Lyon Joseph Douglas	Officer	Nov 03 '25	Proposed Sale	73.47	5,000	367,350		Nov 03 03:31 PM
Maduck Sean	Officer	Nov 03 '25	Proposed Sale	73.47	20,000	1,469,400		Nov 03 03:25 PM
Swisher Daniel N JR	Director	Oct 10 '25	Option Exercise	14.08	2,200	30,976	2,200	Oct 15 06:31 PM
Swisher Daniel N JR	Director	Oct 10 '25	Sale	87.54	2,200	192,588	0	Oct 15 06:31 PM
Swisher Daniel N JR	Director	Oct 10 '25	Proposed Sale	87.54	2,200	192,588		Oct 10 10:44 AM
Guyer William	Chief Development Officer	Oct 07 '25	Option Exercise	21.65	20,000	433,000	25,287	Oct 09 05:51 PM
Guyer William	Chief Development Officer	Oct 07 '25	Sale	89.94	20,000	1,798,782	5,287	Oct 09 05:51 PM
Guyer William	Officer	Oct 07 '25	Proposed Sale	89.85	20,000	1,797,000		Oct 07 01:51 PM
BELANOFF JOSEPH K	Chief Executive Officer	Oct 01 '25	Sale	85.08	40,000	3,403,253	2,781,370	Oct 03 05:24 PM
Lyon Joseph Douglas	See Remarks	Oct 01 '25	Option Exercise	13.56	5,000	67,800	15,277	Oct 03 05:17 PM
Lyon Joseph Douglas	See Remarks	Oct 01 '25	Sale	84.75	5,000	423,766	10,277	Oct 03 05:17 PM
Maduck Sean	See Remarks	Oct 01 '25	Option Exercise	7.95	20,000	159,005	27,904	Oct 03 05:15 PM
Maduck Sean	See Remarks	Oct 01 '25	Sale	85.06	20,000	1,701,232	7,904	Oct 03 05:15 PM
BELANOFF JOSEPH K	Officer	Oct 01 '25	Proposed Sale	83.11	40,000	3,324,400		Oct 01 03:34 PM
Maduck Sean	Officer	Oct 01 '25	Proposed Sale	83.11	20,000	1,662,200		Oct 01 01:54 PM
Lyon Joseph Douglas	Officer	Oct 01 '25	Proposed Sale	83.11	5,000	415,550		Oct 01 01:42 PM
Swisher Daniel N JR	Director	Sep 10 '25	Option Exercise	14.08	2,200	30,976	2,200	Sep 11 08:38 PM
Swisher Daniel N JR	Director	Sep 10 '25	Sale	72.45	2,200	159,390	0	Sep 11 08:38 PM
Swisher Daniel N JR	Director	Sep 10 '25	Proposed Sale	72.45	2,200	159,390		Sep 10 09:50 AM
Cannon Gillian	Director	Sep 04 '25	Option Exercise	22.99	11,000	252,890	11,000	Sep 08 08:20 PM
Guyer William	Chief Development Officer	Sep 02 '25	Option Exercise	21.65	20,000	433,000	25,487	Sep 04 07:59 PM
Guyer William	Chief Development Officer	Sep 02 '25	Sale	70.49	20,000	1,409,848	5,487	Sep 04 07:59 PM
Lyon Joseph Douglas	See Remarks	Sep 02 '25	Option Exercise	13.56	5,000	67,800	15,066	Sep 04 07:56 PM
Lyon Joseph Douglas	See Remarks	Sep 02 '25	Sale	70.25	5,000	351,247	10,066	Sep 04 07:56 PM
Maduck Sean	See Remarks	Sep 02 '25	Option Exercise	5.05	20,000	101,000	27,681	Sep 04 07:54 PM
Maduck Sean	See Remarks	Sep 02 '25	Sale	70.49	20,000	1,409,828	7,681	Sep 04 07:54 PM
BELANOFF JOSEPH K	Chief Executive Officer	Sep 02 '25	Sale	70.53	40,000	2,821,033	2,821,370	Sep 04 07:54 PM
Guyer William	Officer	Sep 02 '25	Proposed Sale	69.72	20,000	1,394,400		Sep 02 04:31 PM
Maduck Sean	Officer	Sep 02 '25	Proposed Sale	69.72	20,000	1,394,400		Sep 02 04:23 PM
Lyon Joseph Douglas	Officer	Sep 02 '25	Proposed Sale	69.72	5,000	348,600		Sep 02 04:16 PM
BELANOFF JOSEPH K	Officer	Sep 02 '25	Proposed Sale	69.72	40,000	2,788,800		Sep 02 04:09 PM
Robb Gary Charles	Chief Business Officer	Aug 22 '25	Option Exercise	3.88	5,000	19,400	18,364	Aug 26 06:56 PM
Robb Gary Charles	Chief Business Officer	Aug 22 '25	Sale	71.27	2,326	165,774	16,038	Aug 26 06:56 PM
Robb Gary Charles	Officer	Aug 22 '25	Proposed Sale	71.27	2,326	165,774		Aug 22 10:58 AM
Swisher Daniel N JR	Director	Aug 11 '25	Option Exercise	14.08	2,200	30,976	2,200	Aug 12 07:22 PM
Swisher Daniel N JR	Director	Aug 11 '25	Sale	72.30	2,200	159,060	0	Aug 12 07:22 PM
Guyer William	Chief Development Officer	Aug 08 '25	Option Exercise	21.65	35,007	757,902	40,494	Aug 12 07:19 PM
Guyer William	Chief Development Officer	Aug 08 '25	Sale	71.77	35,007	2,512,452	5,487	Aug 12 07:19 PM
Swisher Daniel N JR	Director	Aug 11 '25	Proposed Sale	72.30	2,200	159,060		Aug 11 10:20 AM
Guyer William	Chief Development Officer	Aug 05 '25	Option Exercise	21.65	14	303	5,501	Aug 07 07:17 PM
Guyer William	Chief Development Officer	Aug 05 '25	Sale	71.77	14	1,005	5,487	Aug 07 07:17 PM
Maduck Sean	See Remarks	Aug 01 '25	Option Exercise	5.05	35,007	176,785	42,688	Aug 05 06:51 PM
Maduck Sean	See Remarks	Aug 01 '25	Sale	67.79	35,007	2,373,237	7,681	Aug 05 06:51 PM
BELANOFF JOSEPH K	Chief Executive Officer	Aug 01 '25	Sale	68.53	40,000	2,741,207	2,861,370	Aug 05 06:51 PM
Lyon Joseph Douglas	See Remarks	Aug 01 '25	Option Exercise	13.56	5,823	78,960	15,889	Aug 05 06:47 PM
Lyon Joseph Douglas	See Remarks	Aug 01 '25	Sale	67.51	5,823	393,128	10,066	Aug 05 06:47 PM
Guyer William	Officer	Aug 05 '25	Proposed Sale	71.77	20,000	1,435,400		Aug 05 01:05 PM
Lyon Joseph Douglas	Officer	Aug 01 '25	Proposed Sale	67.17	5,000	335,850		Aug 01 11:25 AM
Maduck Sean	Officer	Aug 01 '25	Proposed Sale	67.15	20,000	1,343,000		Aug 01 11:11 AM
BELANOFF JOSEPH K	Officer	Aug 01 '25	Proposed Sale	67.17	615	41,310		Aug 01 11:00 AM
Maduck Sean	See Remarks	Jul 17 '25	Option Exercise	5.05	4,315	21,791	22,020	Jul 21 07:14 PM
Maduck Sean	See Remarks	Jul 18 '25	Option Exercise	5.05	473	2,389	18,178	Jul 21 07:14 PM
Maduck Sean	See Remarks	Jul 17 '25	Sale	73.48	4,315	317,054	17,705	Jul 21 07:14 PM
Maduck Sean	See Remarks	Jul 18 '25	Sale	73.44	473	34,737	17,705	Jul 21 07:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CORT

Corcept Therapeutics Inc

Upgrade your Finviz experience